Biogen Inc.
Location
Massachusetts
Founded
1978-02-28
Website
Risk Signals
6605 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Pharmaceutical Preparations, Biological Products, Except Diagnostic Substances, Commercial Physical and Biological Research), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about Biogen Inc.
Live alerts from global media, monitored by Business Radar
2025-02-09 (marketbeat.com)
Entropy Technologies LP Acquires New Holdings in Biogen Inc. (NASDAQ:BIIB)
Entropy Technologies LP bought a new stake in Biogen Inc. (NASDAQ:BIIB - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 34,397 shares of the biotechnology company's stock, valued at approximately $5,260,000.
Read more
2025-01-15 (biospace.com)
Under Pressure to Deal, Biogen Executives Deflect Urgency at JPM25 -
While investors and analysts push for a deal, Biogen CEO Chris Viehbacher and Head of Development Priya Singhal refuse to make one out of desperation.
Read more
2025-01-08 (marketbeat.com)
Farmers Trust Co. Acquires New Position in Biogen Inc. (NASDAQ:BIIB)
Farmers Trust Co. purchased a new position in Biogen Inc. (NASDAQ:BIIB - Free Report) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 12,849 shares of the biotechnology company's stock, valued at approximately $1,965,000.
Read more
2024-06-13 (globenewswire.com)
Kirby McInerney LLP Reminds Biogen, Inc. (BIIB) Investors of Class Action Filing and Encourages Investors to Contact the Firm
NEW YORK, June 13, 2024 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP reminds investors that a class action lawsuit has been filed in the U.S....
Read more
2024-03-09 (finmarket.ru)
S&P 500 Updates Record, Nasdaq Up 1.5%
US stock indices ended Tuesday's trading with strong growth. The stock markets of the largest Asia-Pacific countries are generally growing on Wednesday. Oil prices are rising on Wednesday morning, with Brent trading at $82.4 per barrel.
Read more
2019-06-06 (barrons.com)
Biogen Stock Is Slipping Because Investors Don’t Buy Its News on Lou Gehrig’s Disease
In a webcast, the company highlighted two drugs aimed at treating so-called familial ALS, which afflicts a small subset of people suffering from the disease. Those drugs, called tofersen and BIIB0708, are being tested in human trials.
Read more
2019-04-29 (fiercepharma.com)
Under-pressure Biogen aims to please restive investors with bigger, better board
Biogen knows what it's like to confront rebellious investors. | Biogen has faced rebellious investors before. Ten years ago, it confronted a proxy fight with activist Carl Icahn that ended with two new directors on its board.
Read more
2017-07-17 (barrons.com)
Biotechs in Focus Ahead of Earnings
Biogen could update guidance. Gilead Sciences investors will likely focus on whether a deal is on or not.
Read more
2012-06-09 (barrons.com)
Shake It Up: Of Mice and Markets
Edited by Robin Goldwyn Blumenthal
Read more
2009-06-04 (bostonherald.com)
Biogen announces early board election results Icahn pick named
Biogen Idec Inc. has announced preliminary results of its board elections, saying that “it appears” that shareholders have chosen Alex Denner, Robert Pangia, William Young have won seats. Denner is one of billionaire investor Carl Icahn’s hand-picked nominees for four board seats that were available. The biotechnology giant said the voting for a fourth director […]
Read more
2009-06-03 (bostonherald.com)
Two Icahn nominees declare victory
Billionaire investor Carl Icahn may have won two board seats in his proxy battle with biotechnology company Biogen Idec Inc., said Alex Denner, an Icahn associate and nominee for the board. Denner returned to the company’s annual meeting at 1:40 p.m. after a recess and said that he and Dr. Richard C. Mulligan, another Icahn […]
Read more